KOSDAQMachinery263920

HuM&C

₩2,490▼ 1.39%2026-11-18 close
Market Cap
₩24.4B
Turnover
₩2,699,013
Volume
1.1K
Shares out.
9.8M
PER
9.9×
PBR
0.6×
EPS
₩266
Dividend Yield
7.62%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

HuM&C: Quarterly Profit Recovers After a Weak 2025

Operating profit fell 49.8% in 2025, but quarterly operating profit has recovered through 2026, and the key question is whether margins hold as the Vietnam plant expands.

  1. 1

    Operating profit was KRW 2.48 billion in 2025, down 49.8% year on year, and the 4.7% operating margin is the lowest of 2022 to 2025.

  2. 2

    Quarterly operating profit reached KRW 823 million in Q1 2026, KRW 1.24 billion in Q2 and KRW 1.02 billion in Q3, up from the Q4 2025 low.

  3. 3

    In Q3 2026 the glass segment sold KRW 9.0 billion (up 10% year on year), the cosmetics segment KRW 6.0 billion (up 15%), and export sales rose about 30%.

  4. 4

    Net profit attributable to controlling shareholders fell to KRW 94.17 million in Q3 2026, which the company attributed to foreign-currency translation losses after the won weakened.

  5. 5

    Funding for the Vietnam subsidiary's expansion and the share buyback running through December 11, 2026 are the next items to watch.

02

Business structure

HuM&C is a healthcare packaging and materials specialist within the Huons Group. It reports two segments, glass and cosmetics. The glass segment is led by ampoules and cartridges used in anesthetics, and higher output efficiency at its Vietnamese production base, HuM&C Vina, has lifted sales.

In Q3 2026 glass sales were KRW 9.0 billion, up 10% year on year, out of total revenue of KRW 15.0 billion. The cosmetics segment reflects overseas customers' finished-product orders as K-beauty spreads, and its Q3 2026 sales were KRW 6.0 billion, up 15% year on year.

Export sales in Q3 2026 rose about 30% year on year. The Vietnam plant is in Hung Yen Province, covers 14,876 square meters, and can produce 60 million vials and 90 million cartridges a year. The plant was completed in December 2024, and its production lines began full operation in the second quarter of 2025.

The company is described as a small but strong firm with a one-stop line that compounds and produces NBR-based materials in-house. Although it sits in the same machinery and equipment sector, its customers and cost structure differ from listed peers that make robots or construction machinery. It competes with domestic and foreign makers of medical and cosmetic packaging components.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩13.4B₩700M5.5%
2025Q4₩13B₩500M3.6%
2026Q1₩14.5B₩800M5.7%
2026Q2₩15.7B₩1.2B7.9%
2026Q3₩15B₩1B6.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩35.6B₩1.8B₩800M5.0%2.6%54.3%
2023₩48.4B₩4.8B₩10.3B10.0%25.5%35.9%
2024₩47.2B₩4.9B₩3.4B10.5%7.7%40.9%
2025₩52.3B₩2.5B₩1.6B4.7%3.5%35.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

HuM&C's reported results peaked in 2023 and then declined in 2024 and 2025. Revenue rose from KRW 35.6 billion in 2022 to KRW 48.4 billion in 2023 (up 35.9% year on year), eased to KRW 47.2 billion in 2024 (down 2.5%), and reached KRW 52.3 billion in 2025 (up 10.8%), the largest year in the 2022 to 2025 window.

Operating profit went from KRW 1.77 billion in 2022 to KRW 4.84 billion in 2023 (up 174.1%) and KRW 4.95 billion in 2024 (up 2.2%), then fell to KRW 2.48 billion in 2025 (down 49.8%).

The operating margin moved from 5.0% in 2022 to 10.0% in 2023 and 10.5% in 2024 before dropping to 4.7% in 2025, so the margin fell in the year revenue grew most.

Net profit attributable to controlling shareholders rose from KRW 798 million in 2022 to KRW 10.3 billion in 2023 (up 1,191.3%), the peak, then fell to KRW 3.4 billion in 2024 (down 67.0%) and KRW 1.57 billion in 2025 (down 53.8%), declining for two consecutive years from 2024 to 2025.

Net profit including non-controlling interests was reported at the same amounts in each of those years. Net profit in 2023 well exceeded operating profit of KRW 4.84 billion, which points to non-operating items that the next annual report's income statement should clarify.

At the end of 2025, total equity was KRW 45.5 billion, all of it attributable to controlling shareholders, total liabilities were KRW 16.3 billion, and the debt ratio was 35.8%. Operating cash flow was KRW 2.07 billion in 2022, KRW 6.14 billion in 2023, KRW 4.91 billion in 2024 and KRW 4.96 billion in 2025.

On a quarterly basis, Q3 2025 revenue was KRW 13.4 billion with operating profit of KRW 730 million, and Q4 2025 revenue of KRW 13 billion (down 2.9% quarter on quarter) with operating profit of KRW 464 million (down 36.3%) marked the low point.

Q1 2026 revenue was KRW 14.5 billion with operating profit of KRW 823 million (up 77.2%), and Q2 2026 revenue was KRW 15.7 billion with operating profit of KRW 1.24 billion, the highest quarterly operating profit in the reported window.

Q3 2026 revenue was KRW 15 billion (down 4.4% quarter on quarter, up 11.9% year on year) and operating profit was KRW 1.02 billion (down 18.0% quarter on quarter, up 39.8% year on year).

Net profit attributable to controlling shareholders was KRW 94.17 million, down 90.4% quarter on quarter and 85.8% year on year, which the company attributed to foreign-currency translation losses as the won weakened.

Over the last four reported quarters, net profit attributable to controlling shareholders totaled KRW 2.62 billion. The company described Q1 2026 as its best quarterly result on record, citing better cost ratios, demand for vials used in health functional foods, and the start of Vietnam production.

05

Industry analysis

HuM&C's end demand comes from three areas: pharmaceutical packaging, health functional foods and cosmetics. In June 2026 the company said higher sales of health functional foods had lifted demand for vial containers.

The same explanation pointed to rising demand for prefilled syringes as the cosmetics and beauty market expands. Anesthetic demand has also grown at home and abroad, supporting ampoule and cartridge sales in the glass segment.

K-beauty's reach has widened from Asia to the United States and Europe, lifting finished-product orders from overseas customers. However, demand rests on three drivers, health functional foods, anesthetics and K-beauty, so a slowdown in any one could weigh on total volume.

Public industry indicators that would show whether the cycle is near a peak or a trough are not easily linked to this company's results. On competition, the company has stressed price competitiveness from its Vietnamese base.

Export sales rising about 30% in Q3 2026 shows a growing overseas share of revenue, but it also means overseas receivables are exposed to currency moves. The company has said it will keep looking for cooperation opportunities with global pharmaceutical and biotech companies.

Among listed firms in the same machinery and equipment sector, companies that make robots or construction machinery serve different demand bases than HuM&C, which supplies medical and cosmetic components.

06

Outlook

The near-term items to watch are the Vietnam expansion and how its funding is used. On November 12, 2026, the company disclosed that it will extend the maturity of the existing USD 5.1 million loan to its subsidiary HuM&C Vina and make a new USD 700,000 loan.

The funds are planned for facility upgrades and expansion, to meet supply demand from new customers. The Vietnam plant already has annual capacity of 60 million vials and 90 million cartridges and is now moving toward further expansion.

Under a June 2026 board resolution, the company will buy back KRW 1.0 billion of its shares through a trust agreement with Samsung Securities, over six months through December 11, 2026. Reports say the planned purchase is 315,493 shares, which would lift treasury stock from 0.01% to 3.6% of shares outstanding.

In February 2026 the company paid a cash dividend for the first time since its founding, and the dividend decision at the next annual general meeting will show whether the return policy continues.

The chief executive has said the company aims to strengthen its market position through balanced growth across businesses and to develop new products. In the next annual report, the key item to watch is how much of the Vietnam capacity shows up in glass segment sales and operating margin.

The cosmetics segment has stayed profitable since turning a profit in Q2 2026, but its cumulative profit record is still short. Q4 2026 results will be disclosed in the 2026 annual report.

07

Valuation

PER
9.9×
PBR
0.6×
ROE
5.8%
EPS
₩266
BPS
₩4,537
Dividend per share
₩200

HuM&C's share price sits at a low level relative to its net assets. Its price-to-book ratio is below 1x, so the stock trades at a discount to book value of KRW 45.5 billion, all attributable to controlling shareholders.

On earnings, a multiple based on the KRW 2.62 billion of net profit attributable to controlling shareholders over the last four quarters is sensitive to quarterly swings.

Compared with the 2023 peak of KRW 10.3 billion in net profit attributable to controlling shareholders, the earnings base is smaller through 2025, so how the multiple reads depends on how far that base recovers.

Because the earnings multiple depends on whether earnings normalize, it should be read alongside whether the 2026 quarterly recovery continues from the 4.7% operating margin in 2025. The first cash dividend was paid in 2026, so the dividend record is short, and the dividend yield moves with the share price.

The ongoing share buyback is a fact to note under shareholder returns. Given the small market capitalization, trading liquidity and price volatility are relatively high, which is also worth factoring into any valuation reading.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Vietnam production base and glass demand

The Vietnam plant, HuM&C Vina, was completed in December 2024 and has annual capacity of 60 million vials and 90 million cartridges. Q3 2026 glass sales were KRW 9.0 billion, up 10% year on year, supported by higher anesthetic demand for ampoules and cartridges.

In November 2026 the company extended a loan to the Vietnam subsidiary and approved a new one, signaling its expansion plans.

Recovery in quarterly operating profit

Operating profit bottomed at KRW 464 million in Q4 2025 and then rose to KRW 823 million in Q1 2026, KRW 1.24 billion in Q2 and KRW 1.02 billion in Q3. Q3 2026 operating profit was up 39.8% year on year, with revenue and operating profit growing together.

The company attributed the Q1 2026 result to better cost ratios and higher demand for vials used in health functional foods.

Start of shareholder returns

In June 2026 its board approved a KRW 1.0 billion share buyback, to be executed through a trust agreement with Samsung Securities until December 11, 2026. The company describes the buyback as a sign of its commitment to shareholder value.

09

Bear factors

Profit decline and low margin in 2025

Net profit attributable to controlling shareholders declined for two consecutive years from 2024 to 2025. Profit fell even though revenue reached KRW 52.3 billion, the largest year in the window, and that is the starting point of the bearish case.

Sharp drop in Q3 net profit

Net profit attributable to controlling shareholders was KRW 94.17 million in Q3 2026, down 85.8% year on year. The company cited foreign-currency translation losses as the won weakened. Operating improvement and net profit moved in different directions, so the quality of earnings needs closer scrutiny.

Short profitability record in cosmetics

In Q1 2026 cosmetics sales were KRW 4.6 billion, down 10% year on year, and the loss narrowed by 43%. The segment turned profitable in Q2 2026 and stayed profitable in Q3, but its cumulative profit record is short. Because it relies on overseas finished-product orders, profit may swing with order volumes.

10

Risk factors

Currency and translation losses

Loans to the Vietnam subsidiary are denominated in dollars, so currency moves can create translation losses. In Q3 2026 a sharp fall in the won increased such losses and sharply reduced net profit attributable to controlling shareholders. If loan balances grow with expansion, the same volatility could increase.

Demand concentration and utilization of new capacity

The glass segment depends on anesthetic and health functional food demand, and the cosmetics segment on overseas finished-product orders. If demand in either area weakens or new customers are slow to arrive, utilization of the expanded capacity could fall. How far utilization feeds into results after the investment is a key point to monitor.

Small-cap characteristics and trading conditions

With a small market capitalization, trading volume can be thin and share price volatility can be large. As a member of the Huons Group, group-level transactions and support could affect results and the share price. The buyback period and the share price trend should be reviewed together.

11

What to watch next

  1. December 11, 2026

    The end of the planned share buyback period. The amount actually acquired under the trust agreement will show how far shareholder returns were executed.

  2. February 2027 annual general meeting

    Whether the first cash dividend paid in 2026 becomes a regular practice. The dividend decision will indicate whether the return policy continues.

  3. March 31, 2027 (statutory deadline for the annual report)

    The 2026 annual report will disclose Q4 and full-year 2026 results. The key question is how far the annual operating margin recovers from 4.7% in 2025.

  4. May 15, 2027 (statutory deadline for the Q1 quarterly report)

    The Q1 2027 report will show whether the Vietnam expansion is reflected in sales and profit and whether the cosmetics segment stays profitable.

12

Overall view

HuM&C's reported net profit attributable to controlling shareholders peaked in 2023 and declined in 2024 and 2025, and the 4.7% operating margin in 2025 was the lowest in the reported window.

Quarterly operating profit recovered through 2026, reaching KRW 823 million in Q1, KRW 1.24 billion in Q2 and KRW 1.02 billion in Q3. Both the glass and cosmetics segments grew and overseas exports rose, but Q3 2026 net profit fell sharply on currency translation losses.

The Vietnam plant has production capacity and its expansion funding is moving forward, which broadens the operating base. Shareholder returns have also begun, with the first dividend in 2026 and the share buyback. However, the cosmetics segment's profit record is short, and net profit is sensitive to currency moves.

The next checkpoints are the end of the buyback on December 11, 2026, the annual operating margin in the 2026 annual report, and the effect of the expansion in the Q1 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. iminju.net
  2. medipharmhealth.co.kr
  3. medipana.com
  4. thebionews.net
  5. thefairnews.co.kr
  6. pharmnews.com
  7. datasom.co.kr
  8. worktoday.co.kr
  9. lawissue.co.kr
  10. hankyung.com
  11. ebn.co.kr
  12. news1.kr
  13. biztribune.co.kr
  14. paxetv.com
  15. inthenews.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis